Failed Leads
Are Not Failures.
Every inactive compound, every negative screen, every discontinued program contains scientific intelligence that the field desperately needs. The Negative Data Hub is where that intelligence gets shared — and put to work.
Why Negative Data Is
Scientifically Essential
This isn't about being generous. It's about the fundamental logic of drug discovery — and why the field has been systematically inefficient by treating negative results as waste.
SAR Boundary Mapping
Inactive analogs define the edges of structure-activity relationships just as precisely as active ones. Without negative data, SAR maps have blind spots that lead to wasted synthesis cycles.
Machine Learning Training
ML models trained only on positive hits are systematically biased. Balanced datasets with negative examples dramatically improve predictive accuracy for virtual screening and ADMET prediction.
Selectivity Profiling
Knowing which targets a compound does NOT hit is as important as knowing what it does hit. Negative selectivity data is the foundation of safety pharmacology and off-target risk assessment.
Scaffold Repurposing
A scaffold that failed for Target A may be perfectly suited for Target B. Negative data from one program is often the starting point for another — if it's shared rather than archived.
Publication Bias Is
Costing the Field Billions.
Scientific journals have historically published positive results at a rate of 85–90%. This creates a systematic distortion: the field sees only what worked, never what didn't. Labs repeat failed experiments in isolation, burning resources on paths already proven to be dead ends.
The Negative Data Hub exists to correct this distortion — not by publishing papers, but by creating a living, searchable, actionable database of what the field has already learned the hard way.
What Happens When Labs
Share What Didn't Work
How 380 Inactive Kinase Inhibitors Saved 3 Labs 18 Months of Work
18 months savedWhen Vertex shared their inactive kinase inhibitor dataset — 380 compounds that failed selectivity screens — three partner labs immediately identified overlapping chemical space with their own programs. All three pivoted their scaffold strategies within 6 weeks, avoiding a combined 18 months of redundant synthesis and screening.
Key lesson: Negative data defines the boundary of what doesn't work — which is exactly what you need to know before investing in synthesis.
GPCR Negative Panel Eliminated Duplicate Screening Across 8 Labs
$2.4M in avoided costsScripps Research shared a comprehensive negative screening dataset across 45 GPCR targets — 1,200 compounds, all inactive at 10µM. Eight labs in the network were planning to screen overlapping compound sets against the same targets. The shared dataset eliminated all duplicate work, saving an estimated $2.4M in combined screening costs.
Key lesson: In a field where HTS campaigns cost $4,000–$50,000 each, knowing what's already been tested is worth more than the positive hits.
Discontinued CNS Program Entered Phase I Within 18 Months of Licensing
Phase I in 18 monthsA CNS program halted by Neurovance due to a strategic pivot — not safety concerns — contained 6 lead scaffolds, 240 analogs, full BBB permeability data, rodent PK, and 28-day tox data. An emerging biotech licensed the full asset package and entered Phase I within 18 months, bypassing years of early-stage work.
Key lesson: A discontinued program is not a failed program. Strategic pivots leave behind fully characterized assets that can launch new companies.
Why Labs Don't Share —
And Why They Should
Click each myth to see the reality.
How to Share Your
Negative Data
Three paths — from fully open to fully protected. You choose the level of sharing that works for your institution and IP situation.
Open Share
Post your negative dataset openly. Anyone in the network can access it. Best for academic labs, published data, or programs with no remaining IP value.
Data Exchange
Share your negative data in exchange for complementary datasets from other labs. Bridge BioHealth facilitates the match and MTA execution.
IP-Protected Share
License your negative data or discontinued program assets for a fee or royalty. Bridge BioHealth helps structure the deal and identify buyers.
Ready to Share What Didn't Work?
Your negative data is more valuable than you think. List it on BioShare, exchange it for something you need, or license it for revenue. The field moves faster when we share what we know.